<table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 18: The Effect of Quetiapine on the Pharmacokinetics of Other Drugs 
</caption>
<tbody>
<tr>
<td>
<content stylecode="bold">Coadministered drug</content>
<br/>
</td>
<td>
<content stylecode="bold">Dose schedules</content>
<br/>
</td>
<td>
<content stylecode="bold">Effect on other drugs pharmacokinetics</content>
<br/>
</td>
</tr>
<tr>
<td> <br/>
</td>
<td>
<content stylecode="bold">Coadministered drug</content>
<br/>
</td>
<td>
<content stylecode="bold">Quetiapine</content>
<br/>
</td>
<td> <br/>
</td>
</tr>
<tr>
<td>Lorazepam <br/>
</td>
<td>2 mg, single dose <br/>
</td>
<td>250 mg three times daily <br/>
</td>
<td>Oral clearance of lorazepam reduced by 20% <br/>
</td>
</tr>
<tr>
<td>Divalproex <br/>
</td>
<td>500 mg twice daily <br/>
</td>
<td>150 mg twice daily <br/>
</td>
<td>C<sub>max</sub> and AUC of free valproic acid at steady-state was decreased by 10­ to 12% <br/>
</td>
</tr>
<tr>
<td>Lithium<br/>
</td>
<td>Up to 2400 mg/day given in twice daily doses <br/>
</td>
<td>250 mg three times daily <br/>
</td>
<td>No effect on steady-state pharmacokinetics of lithium <br/>
</td>
</tr>
<tr>
<td>Antipyrine <br/>
</td>
<td>1 g, single dose <br/>
</td>
<td>250 mg three times daily <br/>
</td>
<td>No effect on clearance of antipyrine or urinary recovery of its metabolites <br/>
</td>
</tr>
</tbody>
</table>